Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantationBruno Paiva, Jesús F. San Miguel, María‐Belén Vídriales et al.|Blood|2008Cited by 479
Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose TherapyGema Mateo, Jesús F. San Miguel, María-Ángeles Montalbán et al.|Journal of Clinical Oncology|2008Cited by 210
Genetic Abnormalities and Patterns of Antigenic Expression in Multiple MyelomaGema Mateo, Jesús F. San Miguel, Mariana Castellanos et al.|Clinical Cancer Research|2005Cited by 126
The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patientsBruno Paiva, María‐Belén Vídriales, Gema Mateo et al.|Blood|2009Cited by 75
Evaluation of minimal residual disease in multiple myeloma patients by fluorescent‐polymerase chain reaction: the prognostic impact of achieving molecular responsePilar Martínez‐Sánchez, Joaquín Martínez‐López, Juan José Lahuerta et al.|British Journal of Haematology|2008Cited by 58